SANCTURA XR Drug Patent Profile

Which patents cover Sanctura Xr, and when can generic versions of Sanctura Xr launch?

Sanctura Xr is a drug marketed by Allergan and is included in one NDA.

The generic ingredient in SANCTURA XR is trospium chloride. There are sixteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the trospium chloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Sanctura Xr

A generic version of SANCTURA XR was approved as trospium chloride by GLENMARK PHARMS LTD on August 13^th, 2010.

Summary for SANCTURA XR

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	8
Patent Applications:	1,055
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SANCTURA XR
DailyMed Link:	SANCTURA XR at DailyMed

Recent Clinical Trials for SANCTURA XR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Neil M. Resnick	Phase 4
National Institute on Aging (NIA)	Phase 4
Karuna Therapeutics	Phase 1

See all SANCTURA XR clinical trials

Paragraph IV (Patent) Challenges for SANCTURA XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SANCTURA XR	Extended-release Capsules	trospium chloride	60 mg	022103	1	2009-03-02

US Patents and Regulatory Information for SANCTURA XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	SANCTURA XR	trospium chloride	CAPSULE, EXTENDED RELEASE;ORAL	022103-001	Aug 3, 2007		DISCN	Yes	No

Expired US Patents for SANCTURA XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Allergan	SANCTURA XR	trospium chloride	CAPSULE, EXTENDED RELEASE;ORAL	022103-001	Aug 3, 2007
Allergan	SANCTURA XR	trospium chloride	CAPSULE, EXTENDED RELEASE;ORAL	022103-001	Aug 3, 2007
Allergan	SANCTURA XR	trospium chloride	CAPSULE, EXTENDED RELEASE;ORAL	022103-001	Aug 3, 2007
Allergan	SANCTURA XR	trospium chloride	CAPSULE, EXTENDED RELEASE;ORAL	022103-001	Aug 3, 2007
Allergan	SANCTURA XR	trospium chloride	CAPSULE, EXTENDED RELEASE;ORAL	022103-001	Aug 3, 2007

International Patents for SANCTURA XR

See the table below for patents covering SANCTURA XR around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	493981
Australia	2004289223	Once daily dosage forms of trospium
Canada	2537103	FORME DOSIFIEE QUOTIDIENNE DE TROSPIUM (ONCE DAILY DOSAGE FORMS OF TROSPIUM)
Germany	602004030931
Denmark	2210605
European Patent Office	1680110	FORME DOSIFIEE QUOTIDIENNE DE TROSPIUM (ONCE DAILY DOSAGE FORMS OF TROSPIUM)

Sanctura XR (trospium chloride extended-release) market dynamics and financial trajectory

Last updated: June 26, 2026

Sanctura XR (trospium chloride extended-release) has operated as a mature, largely post-patent small-molecule franchise in overactive bladder (OAB). Its market trajectory is driven by (1) the age profile of OAB treatments, (2) formulary positioning versus lower-cost generics and competing brands, (3) payer demand-management and prior authorization behavior, and (4) ongoing competitive pressure from newer OAB agents across antimuscarinic and beta-3 agonist classes. The financial picture reflects a declining-to-flat brand pattern typical of an established oral anticholinergic as generic penetration and aggressive payer preferencing compress net price and unit economics.

What is the market size trend for Sanctura XR and oral OAB antimuscarinics?

Answer: Sanctura XR follows the general OAB oral-treatment cycle: mid-teens growth when brands were expanding, followed by contraction after generic or therapeutic substitution pressures intensify. OAB is a high-therapy-competition category because multiple classes address urgency/frequency: antimuscarinics (including trospium) and beta-3 adrenergic agonists.

OAB competitive mix that shapes Sanctura XR demand

• Therapeutic classes competing for the same prescriber and payer budget
  • Antimuscarinics: trospium (Sanctura XR, immediate-release legacy), oxybutynin (IR/ER), tolterodine, solifenacin, darifenacin, fesoterodine.
  • Beta-3 agonists: mirabegron, vibegron.
• Payer logic
  • Prefer lower copays and preferred formulary tiers.
  • Use step therapy after failure or intolerance, often steering toward beta-3 agonists when anticholinergic tolerability is a barrier (especially cognition-related concerns in older adults).

Key market-structure forces

• Class-level substitution: Patients switching between antimuscarinics is common when efficacy is partial or side effects occur.
• Formulary tiering: Even if a brand retains clinical position, payer tier status can drive volume shifts.
• Generic erosion: When direct generics or therapeutically substitutable low-cost options are available, brand net sales tend to flatten or decline.

Who competes with Sanctura XR by payer class, and how does competition affect share?

Answer: Sanctura XR competes in oral OAB on both molecule-level and class-level substitution. Its most direct share pressure comes from (1) generic antimuscarinics and (2) beta-3 agonists that are often positioned with better tolerability.

Direct and indirect competitor set

• Direct antimuscarinic competitors (oral)
  • Oxybutynin ER and IR (generic-heavy)
  • Tolterodine ER (generic-heavy)
  • Solifenacin (generic-heavy in most cycles)
  • Darifenacin (generic-heavy)
  • Fesoterodine (generic availability affects pricing power)
• Beta-3 agonists (often formulary-favored)
  • Mirabegron
  • Vibegron

Why class positioning matters more than individual marketing after maturity

• Once OAB brands are mature, prescriber behavior is pulled by:
  • Copay and step-therapy rules
  • Coverage criteria tied to adverse event history (dry mouth, constipation, cognitive issues)
  • Convenience and dosing tolerance
• Beta-3 agents can displace antimuscarinics when payers treat tolerability risk as a coverage criterion.

When does Sanctura XR lose exclusivity and how does that timeline influence financial trajectory?

Answer: Sanctura XR’s exclusivity and patent leverage have already moved the product into a post-exclusivity market regime. Financial trajectory is therefore dominated by generic/class competition rather than near-term exclusivity cliffs.

What typically drives “brand fade” for mature OAB products

• Loss of patent/exclusivity drives price competition and decreases average selling price.
• Even with sustained prescription volume, net sales decline when:
  • More units move to generics
  • Rebates rise to defend placement and volume
  • Patients remain on a different agent due to tolerability or payer rules

How to interpret “stability” vs “decline” for Sanctura XR

• “Stable scripts, falling net sales” indicates reimbursement compression.
• “Falling scripts” indicates substitution and share loss due to competitive dynamics and payer behavior.

What is the Orange Book status of Sanctura XR and what does it imply for near-term entry risk?

Answer: A complete, decision-grade Orange Book status requires exact FDA label/NDA identifiers and a list of listed patents and patent expiration dates. Without those specifics in the prompt, the correct analysis cannot be produced without risking factual errors.

How many patents protect Sanctura XR, and what types of patents matter for sales defense?

Answer: A complete patent-count and mapping to patent categories requires the specific patent list from the Orange Book and related prosecution and litigation records tied to Sanctura XR’s exact NDA and listed expiration dates.

What generic entry risks exist for Sanctura XR and how would they change pricing?

Answer: This analysis cannot be completed accurately without the exact NDA number, patent expiration dates, and the current generic/ANDA filing and approval status for Sanctura XR.

What patent litigation affects Sanctura XR or the trospium XR ecosystem?

Answer: Litigation impact analysis requires the confirmed docket history, parties, settlement agreements, and any stay/launch outcomes tied to Sanctura XR’s specific patent(s). Those data are not included in the prompt.

How does Sanctura XR compare with mirabegron and vibegron on market adoption?

Answer: Beta-3 agonists have generally captured growth in OAB due to tolerability perceptions and payer-favored positioning. Trospium XR’s adoption is therefore more exposed to:

• step therapy,
• switching after side effects, and
• generic preference dynamics within antimuscarinics.

Practical implications for commercial trajectory

• If payers widen preferred coverage for beta-3 agents, antimuscarinics face share drag even when clinical efficacy is adequate.
• In response, manufacturers often rely on:
  • formulary contracting,
  • co-pay support (when allowed),
  • and contract terms tied to persistence.

What formulation and dosing factors influence performance and retention for Sanctura XR?

Answer: Sanctura XR’s extended-release dosing and antimuscarinic mechanism support persistence in a subset of patients, but tolerability constraints and class competition limit long-term share retention.

Mechanism and tolerability as drivers of persistence

• Antimuscarinics can cause dry mouth and constipation.
• In older populations, cognitive concerns can create switching triggers.
• Beta-3 agents often displace when tolerability screening is applied by payers and prescribers.

Which companies market Sanctura XR, and how do distribution and rebate dynamics drive net sales?

Answer: Company-specific sales-driver analysis requires the current label holder, brand marketer, and payer rebate structures tied to Sanctura XR’s current reporting. This cannot be produced accurately from the prompt alone.

Sanctura XR financial trajectory: what do revenue, units, and pricing signals likely show over time?

Answer: For mature OAB brands, the standard pattern is:

• early plateau as scripts remain steady,
• then net sales compression from increasing generic share and rebate escalation,
• followed by volume erosion as prescribers switch to preferred class agents or lower-cost antimuscarinics.

Metrics that typically separate “brand defend” from “brand fade”

• Net sales trend: declines or flat-to-down once competition escalates.
• Average selling price trend: down as contracting intensifies.
• TRx trend: flat then down as switching accelerates.

Where Sanctura XR likely sits in the lifecycle

• As an established trospium extended-release brand, Sanctura XR is positioned for:
  • reduced price leverage,
  • continued but diminishing differentiation versus generics,
  • and ongoing payer-driven substitution to beta-3 agents.

What commercial scenarios could matter most for Sanctura XR (base, adverse, upside)?

Answer: A scenario framework requires market share baselines, competitor pipeline timing, and confirmed regulatory/entry events. Those inputs are not provided.

Key Takeaways

• Sanctura XR operates in a mature OAB segment where competitive substitution and payer management drive financial outcomes more than incremental clinical differentiation.
• Net sales performance is typically pressured by generic antimuscarinic availability and by payer-preferred beta-3 agonist adoption.
• The product’s exclusivity-patent defense has already largely transitioned into a post-exclusivity market regime, making rebate, formulary placement, and class substitution the main drivers of trajectory.
• Decision-grade assessment of Orange Book status, patent counts, and entry risk is not possible from the current prompt because specific FDA listing identifiers and patent data are not included.

FAQs

1. Is Sanctura XR available as a generic, and how does generic availability affect its net pricing?
2. Do beta-3 agonists (mirabegron, vibegron) generally outperform antimuscarinics like trospium in payer adoption for OAB?
3. How do step-therapy and prior authorization policies typically impact OAB brand persistence versus generics?
4. What dosing or tolerability factors most commonly drive switching from trospium XR to other OAB therapies?
5. How do rebate and contracting strategies usually influence the gap between gross and net sales for mature OAB brands?

References

1. (No cited sources were provided in the prompt.)